ERBB2 and breast carcinoma: This new conjugate was tested on HER2-expressing breast cancer cells (MDA-MB-435 and SK-BR-3 cancer cell lines), displaying potency and selective cytotoxicity with EC50 values in the range of 100–400 pM.